Pharmaceuticals

Efcitra demonstrates non-inferiority to insulin glargine and degludec in type 2 diabetes

bexib
By bexib 0 Min Read

Results from the QWINT-1 and QWINT-3 trials showed that insulin-naive patients experienced similar reductions in A1C levels with once-weekly Efcitra compared with daily insulin glargine and degludec.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Optimized landing pages reduce advertising costs
Next Article Calculated risk and reward! July existing home sales increase to 3.95 million SAAR
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Azzaro Group’s exciting new travel offering for 2025 combines the cultural hub of Cape Town with the unspoiled nature of the Okavango Delta
Hospitality & Tourism
Remaking history: Sarah Mather and Aquascope
Manufacturing
Christmas has arrived at Orelle – Luxury Hospitality Magazine
Hospitality & Tourism
A look inside: Allies developing a multicloud hybrid strategy
Banking